These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249 [TBL] [Abstract][Full Text] [Related]
26. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Goto S; Tamura N; Ishida H J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925 [TBL] [Abstract][Full Text] [Related]
27. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba. Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372 [TBL] [Abstract][Full Text] [Related]
28. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade. Matzdorff A; Voss R Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353 [TBL] [Abstract][Full Text] [Related]
29. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54. Naimushin YA; Mazurov AV Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942 [TBL] [Abstract][Full Text] [Related]
30. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160 [TBL] [Abstract][Full Text] [Related]
31. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Derhaschnig U; Pachinger C; Jilma B Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100 [TBL] [Abstract][Full Text] [Related]
32. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439 [TBL] [Abstract][Full Text] [Related]
33. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842 [TBL] [Abstract][Full Text] [Related]
34. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042 [TBL] [Abstract][Full Text] [Related]
35. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173 [TBL] [Abstract][Full Text] [Related]